CoreBone

CoreBone’s coral-based biocactive bone graft material

CoreBone has developed, and is distributing, bioactive, coral-based bone graft material that provides a natural alternative to human and animal-derived (bovine, porcine) bone graft material for dental and orthopedic indications, providing a natural alternative to human and animal derived materials.

CoreBones patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of corals during their growth process to accelerate healing and provide better connectivity. The CoreBone graft offers the same bonelike qualities as organic material (human/animal derived) without the associated risks.

• Similar qualities to human (allograft) bone, but derived from coral
• Better remodeling than bovine products (no heat treatment required); see more in Market
• Attractiveness to growing religious and vegetarian segments
• Competitive pricing
• Approved for dental and orthopedic indications

IP

• U.S. patent (2015)
• Israeli patent
• EU patent pending

Download CoreBone’s Brochure

• October 2019 – CoreBone China established in Guangzhou, CFDA approval in process
• July 2019 – Thousands of successful dental bone grafting cases completed globally; Distribution networks continue to expand
• April 2019 – Successful surgeries using CoreBone material conducted in the Orthopedic Oncology Department at Tel Aviv Sourasky Medical Center
• Sales and distribution in France, Germany, UK, Brazil, Poland, Romania, Kazakhstan, Turkey and Israel
• March 2017 – Product launch
• January 2017 – Israel Ministry of Health approval
• Registration process China, Taiwan and Brazil
• October 2016 – CE mark class III
• Ongoing studies with leading hospitals
• Highly positive feedback from KOLs: “Just like Bio-Oss” (the gold standard, global leader, bovine-derived)

CoreBone booth at DGI Congress, Hamburg, Germany with potential German distributors

Now Funding

In the Media

• ynet: CoreBone is an Israeli success story
• Hamodia: Growing new bones
• Israel21c: Growing new bone from corals raised in the Israeli desert
• Israel21c: Top 12 disruptive technologies to watch in 2015
• CNN Marketplace Middle East: How a coral farm in the desert could help ‘grow bones’

Today, implants are used more and more in dental and orthopedics. In many cases, bone is insufficient, and bone grafts stimulate the growth of new bone to support and anchor the implant. Most bone graft materials in the market are derived from human and animal bone and carry the risk of disease and rejection. *Furthermore, bovine-derived products hardly remodel due to the heat treatment that is essential to reduce viral risks. Synthetic materials, a fast-growing segment, lack strength.

Bone grafts from human and animal origin are in decline due to their associated risks. The synthetic bioactive product share is growing as the market seeks alternatives. The global market for orthopedic bone graft substitutes is expected to reach $3.4 billion by 2022 (Allied Market Research). According to Transparency Market Research, the global dental membrane and bone graft substitutes market is expected to reach $922.6 million by 2024.